Cell surface targeting of recombinant adeno-associated virus (rAAV) vectors is an attractive strategy to modify AAV's natural tropism. As modification of the capsid surface is likely to affect the mechanism of vector internalization and consequently the vector's intracellular fate, we investigated early steps in cell transduction of rAAV capsid insertion mutants. Mutants displaying peptides with neutral overall charge at position 587 transduced cells independently of AAV2's primary receptor heparan sulfate proteoglycan (HSPG), whereas mutants carrying positively charged insertions were capable of HSPG binding with affinities correlating with their net positive charge. Whereas rAAV2 is internalized via an HSPG-and clathrin-dependent pathway, HSPG-binding mutants used a clathrin-and caveolin-independent mechanism. Surprisingly, although this pathway was as efficient in mediating vector entry as the one used by rAAV2, successful cell transduction was hampered at a post-entry step, presumably caused by inefficient endosomal escape. In contrast, HSPG-independent, clathrin-dependent internalization used by non-HSPG-binding mutants correlated with efficient nuclear delivery of vector genomes and robust transgene expression. These findings indicate that cell surface targeting strategies should direct uptake of rAAV targeting vectors to clathrin-mediated endocytosis, the naturally evolved entry route of AAV, to promote successful intracellular processing and re-targeting of rAAV's tropism.
INTRODUCTION
Recombinant adeno-associated viral vectors (rAAV) have emerged as one of the leading gene transfer systems in human clinical trials. 1 However, rAAV's lack of specificity might lead to off-target transduction. Furthermore, both locally as well as systemically applied rAAV particles tend to accumulate in the liver, where anti-capsid immune responses are eventually induced. 2 To avoid off-target transduction, AAV vectors can be engineered to bind to cell-specific receptors (AAV targeting vectors). Although nongenetic cell surface targeting approaches to alter AAV's tropism have been described, genetic modification strategies are more frequently used. 1, 3, 4 In these approaches, peptide ligands are either inserted at the N-terminus of the viral capsid proteins (VP1, VP2) or at surfaceexposed positions within the capsid proteins 1, 3, 4 to mediate target receptor binding (for a review see Büning et al. 1 ). To restrict vector tropism to the desired ligand-receptor interaction, natural receptor binding has to be eliminated at the same time.
Heparan sulfate proteoglycan (HSPG), a negatively charged cell surface molecule, has been identified as the primary receptor for rAAV2. 5 The residues responsible for rAAV2's binding to HSPG (R484, R487, K532, R585 and R588) are located in the common region shared by all AAV capsid proteins. 6, 7 As knockout mutants are barely infectious, [6] [7] [8] it is assumed that HSPG receptor binding is required for rAAV2's interaction with avb5 and a5b1 integrins. 9 Engagement of these integrin co-receptors induces uptake of rAAV2 by clathrinmediated endocytosis, leading to cytoskeletal rearrangements that promote intracellular trafficking of the virus. [9] [10] [11] Insertion of peptide ligands at amino-acid position 587 of the rAAV2 capsid proteins interfere with the integrity of the HSPGbinding motif by separating R585 and R588, 6, 7, 12 but insertion of positively charged peptides may restore the HSPG-binding capacity. 12 In contrast to these vectors, non-HSPG-binding targeting vectors exhibit an altered in vivo distribution with de-targeting from the liver and spleen compared with rAAV2 particles. 12 Here, we aimed to explore the impact of peptide insertions on the choice of the internalization pathway and its consequences for the intracellular processing of rAAV targeting vectors. We therefore compared early steps in cell transduction of AAV capsid insertion mutants that differ in their ability to interact with HSPG. Our study revealed that HSPG-binding mutants employ HSPG for internalization via a clathrin-and caveolin-independent pathway allowing efficient cell entry into various cell types, whereas the non-HSPGbinding mutants entered the cell by receptor-mediated endocytosis via clathrin-coated pits. Surprisingly, only the clathrin-dependent pathway resulted in efficient transgene expression. These findings suggest that highly efficient and cell-type-specific rAAV2 targeting vectors should be designed or selected to transduce cells via an HSPGindependent and clathrin-dependent mechanism.
RESULTS

Selection of non-HSPG-binding and HSPG-binding rAAV2 vectors
Depending on the sequence of the inserted ligand, rAAV2 targeting vectors show the ability/inability to bind to HSPG, 12 the cell surface molecule that functions as the primary receptor for AAV2. 5 In this study, we identified AAV peptide insertion mutants that either regained the ability to bind to HSPG (HSPG-binding mutants) or mutants that transduced cells independently of HSPG (non-HSPGbinding mutants), by performing AAV peptide display on the human chronic myelogenous leukemia cell line K-562, a cell line with low levels of HSPG expression, 13 which we assumed to be beneficial for the selection of non-HSPG-binding mutants. We picked four rAAV2 capsid insertion mutants for further analyses, two with peptides of neutral charge (A2 and C2) and two with peptides of net positive charge (B1: +1 and D5: +3) inserted at position 587 (Supplementary Table 1 ). Of note, C2 and B1 differ in only one of the inserted amino acids. All mutants and the parental serotype AAV2 were packaged as recombinant vectors encoding for enhanced green fluorescent protein (GFP) in a single-stranded vector genome conformation. The capsidto-genomic particle ratio obtained for all vector preparations was comparable and p50, indicating that none of the peptide insertions interfered with vector genome packaging. 6 To assess the influence of HSPG, we next assayed the transduction efficiency of the four mutants, in the presence of heparin, a soluble analogue of HSPG. As a model system, we used the cervix carcinoma cell line HeLa, which is frequently used to study rAAV2-host-cell interactions ( Figure 1a ). In line with our previous results, 12 addition of heparin either abolished (0.7% residual transduction of D5) or significantly inhibited (26% residual transduction of B1) the transduction efficiency of rAAV2 capsid insertion mutants with an overall positively charged peptide insertion, whereas the mutants with neutral insertions (A2 and C2) were not affected.
To further quantify the HSPG-binding ability of B1 and D5, HeLa cells were transduced in the presence of increasing heparin concentrations (Figure 1b) . Interestingly, D5 was significantly more sensitive to heparin-mediated competition than rAAV2. Specifically, for D5 a halfmaximal inhibitory concentration (IC 50 ) of 0.08IUml À1 of heparin was determined, whereas the IC 50 for rAAV2 was 0.8 IU ml À1 of heparin. In contrast, the IC 50 for B1 was B30 IU ml À1 . Therefore, although B1, D5 and rAAV2 all interact with heparin/HSPG, their binding affinities were quantitatively different.
HSPG binding enhances cell entry efficiency
To investigate whether HSPG binding affects the efficiency of vector internalization, we measured the number of intracellular particles of HSPG-binding vs non-HSPG-binding mutants by quantitative PCR following transduction of HeLa (human cervix carcinoma), HEK293 (human embryonic kidney), BLM (human melanoma) and HepG2 cells (human hepatocellular carcinoma). Recombinant AAV2 was used as a control. As illustrated in Figure 2a , rAAV2 and the two HSPG-binding mutants B1 and D5 (Figure 1 ) clearly outperformed the non-binders A2 and C2 with respect to cell entry efficiency, that is, number of intracellular particles. In fact, the internalization efficiency of the HSPG binders B1 and D5 was similar or even better than that of rAAV2.
To monitor the time course of internalization (Figure 2b ), we transduced HeLa cells with equal vector particle numbers of the four capsid mutants or rAAV2, and measured the number of intracellular particles at different time points. Again, the HSPG binders rAAV2, B1 and D5 showed significantly more intracellular particles than the non-HSPG-binding mutants A2 and C2. In particular, 1 h post-transduction (p.t.) the number of intracellular particles for rAAV2 in HeLa cells was B8Â and B12Â higher than for A2 and C2, respectively.
Taken together, these data suggest that the efficiency of internalization of the rAAV2 peptide insertion mutants correlates with their HSPG-binding capacity.
Non-HSPG-binding and HSPG-binding vectors use different cell entry pathways
Clathrin-mediated endocytosis is a common entry pathway for viruses including AAV2. 14 This entry pathway is impaired in the presence of chlorpromazine (CPZ), a drug that inhibits the assembly of clathrin lattices. 15 To investigate if rAAV peptide insertion mutants are internalized via clathrin-mediated endocytosis, we transduced HeLa cells in the presence or absence of CPZ (Figure 3a ). For comparison, HeLa cells were transduced with rAAV2. The effect of CPZ inhibition on clathrin-mediated endocytosis was monitored by imaging studies with fluorescent dye-labeled transferrin (Figure 3b vs c) .
CPZ treatment reduced the transduction rate of the non-HSPG binders A2 and C2 by 67.6% (A2) and 72.0% (C2) (Po0.001), Cell transduction of capsid-engineered rAAV vectors S Uhrig et al respectively, consistent with a clathrin-dependent internalization pathway. In contrast, transduction efficiency of the HSPG-binding mutant D5 was unaffected, leading to the conclusion that transduction of HeLa cells by D5 occurs by a clathrin-independent mechanism. Interestingly, CPZ treatment had no effect on the second HSPGbinding mutant, B1, at the lower particle-to-cell ratio (2Â10 3 ), whereas the transduction efficiency was inhibited at the higher particle-to-cell ratio (5Â10 3 ). Furthermore, although rAAV2 is internalized by a clathrin-dependent pathway, CPZ treatment reduced the transduction rate by only 33.1% (Po0.001; Figure 3a ) compared with untreated controls. 10, 16, 17 Prompted by this observation and the fact that HSPG can serve as internalization receptor for non-viral vectors, 18 we assessed whether rAAV2 could use HSPG as an alternative receptor for vector uptake. Briefly, we incubated HeLa cells with rAAV2 in the presence of CPZ and heparin at a concentration that inhibited transduction by B50% (IC 50 ; Figure 1b) . As a control, transductions were conducted in the presence of either drug or without ( Figure 3d ). As above, treatment with CPZ alone inhibited rAAV2 transduction by approximately 30%, whereas heparin (at the IC 50 ) alone reduced the transduction efficiency by approximately 60%. A notable further increase in the inhibitory effects (B80%) was observed for the combination of heparin and CPZ, consistent with the idea that HSPG could work as an alternative internalization receptor when uptake of rAAV2 by clathrin-mediated endocytosis is blocked. When conducting the same experiment with B1 using the particle-to-cell ratio (5Â10 3 ) at which CPZ impaired B1-mediated cell transduction by approximately 40%, the combination of CPZ and heparin further increased the inhibitory effects compared with heparin alone (45 vs 80% inhibition) (Figure 3d ). Again, this is consistent with HSPG-mediated cell entry as an alternative internalization route for B1. In contrast, cell transduction of D5 did not change notably after the addition of heparin (at the IC 50 ) and CPZ compared with heparin alone, indicating that clathrin-coated pits-in contrast to HSPG-are not involved in cell entry of D5.
Besides clathrin-dependent endocytosis, caveolin-mediated entry routes are frequently used by virions. 14 To determine whether this entry pathway has a role in the uptake of the mutants, we conducted drug inhibition studies with genistein, which blocks caveolinmediated uptake through the inhibition of protein tyrosine kinases. 19 As a positive control, we included rAAV5, a serotype capable of entering cells by both clathrin-and caveolin-mediated endocytosis. 20 Although rAAV5 transduction was inhibited by 40% in the presence of genistein, rAAV2-mediated transduction was unaffected and transduction of the capsid insertion mutants was even increased by up to 43% (D5) (Supplementary Figure 1) .
Collectively, these results point towards a critical role of the ligand in determining the internalization pathway: clathrin-mediated endocytosis is used for cell entry of the non-HSPG-binding mutants A2 and C2 as well as by the HSPG binder B1 at high particle-to-cell ratio. Moreover, the HSPG-binding mutants seem to employ HSPG not only for attachment, but also as alternative (B1) or sole (D5) internalization receptor.
Clathrin-mediated endocytosis is a superior internalization pathway for rAAV capsid mutants As internalization of the non-HSPG-binding mutants A2 and C2 is significantly less efficient than for rAAV2, B1 or D5 (Figure 2 ), a direct comparison of the mutants with respect to intracellular fate is impossible. However, by adjusting the particle-to-cell ratio for equal numbers of intracellular particles this drawback can be overcome. 21 Hence, we increased the particle-to-cell ratio of A2 and C2 by 8.22-and 12.48-fold, respectively, in accordance with the fold-difference in internalization efficiency compared with rAAV2 determined at 1 h p.t. (Figure 2b ). Using this approach, equal numbers of intracellular particles were obtained when transductions were carried out according to a particle-to-cell ratio of 4.11Â10 4 for A2, of 6.21Â10 4 for C2 and of 5Â10 3 for rAAV2, B1 and D5 (Supplementary Figure 2) . Similar results were achieved when the particle-to-cell ratios were adjusted relative to a lower particle-to-cell ratio (Supplementary Figure 2) .
To determine whether the four capsid mutants differed in their ability to overcome post-entry barriers, we measured the number of transgene expressing cells following HeLa cell transduction with adjusted intracellular particle-to-cell ratios ( Figure 4 ). The highest transduction efficiency was obtained with rAAV2, whereas D5-the capsid mutant that uses a clathrin-and caveolin-independent cell entry pathway-showed the lowest transduction efficiency (27 and (Figures 4a and b) . In contrast, no statistically significant difference was observed between the efficacy of cell transduction of the non-HSPG-binding mutants A2 and C2 and rAAV2 (Figures 4a and b) . The significant differences between the HSPG binders D5 and B1 and the non-HSPG-binding mutants A2 and C2 compared with rAAV2 regarding transduction efficiency prompted us to investigate at which post-entry step(s) HSPG-binding mutants are obstructed.
MG-132 is a peptide aldehyde that inhibits the 26S proteasome and has been shown to enhance the transduction efficiency of rAAV2 in hepatocytes, endothelial and lung epithelial cells. [22] [23] [24] Transducing HeLa cells in the presence of MG-132 increased the transduction efficacy of all four mutants and of rAAV2. In particular, we observed a 1.3-fold increase in transduction for rAAV2, 2.2-fold for B1, 1.7-fold for D5, 1.8-fold for A2 and 1.6-fold for C2 (Supplementary Figure 3) . Values represent the mean of at least seven independent experiments, and error bars show s.e.m. Statistical analysis was conducted by two-way ANOVA comparing transduction levels of each vector for the factor treatment (CPZtreated (hatched bars) vs control samples (solid bars)) and for the factor vector dose (high (black bars) vs low (gray bars) particle-per-cell ratio). All pairwise multiple comparison revealed a significant effect of CPZ treatment in case of rAAV2, B1, A2 and C2 (Po0.001). A statistically significant interaction ( # P¼0.031) between vector dose and treatment was observed for B1: Po0.001 for CPZ treated vs control with 5Â10 3 g.p. per cell, whereas CPZ treatment did not significantly influence transduction with 2Â10 3 g.p. per cell (P¼0.156). ***Po0.001; ns, not significant; # , statistically significant interaction between vector dose and treatment (P-values see Supplementary Table 2 ). (b, c) Fluorescence microscopy of HeLa cells incubated with or without 10 mg ml À1 CPZ for 30 min and analyzed for transferrin-Alexa488 (green) and 4¢,6-diamidino-2-phenylindole (blue). Scale bar¼20 mm. Figure 2) .
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Given the marginal differences between the tropism-modified vectors, proteasomal degradation is unlikely to account for the lower transduction rate of HSPG-binding compared with the non-HSPG-binding mutants.
We next studied the kinetics of gene expression as an indicator of the successful release of vector genomes from the viral capsid and transport into the nucleus. Briefly, HeLa cells were transduced with all four rAAV capsid insertion mutants and rAAV2 adjusted for intracellular particles. Following vector binding at 4 1C, cells were incubated for 1 h at 37 1C. Further cell transduction was prevented by the addition of the anti-capsid antibody A20 (Supplementary Figure 4) . Total RNA was extracted at the indicated time points and quantified by RT-qPCR ( Figure 5 ). Our analysis showed that the number of transcripts for all vectors including rAAV2 increased at approximately 2 h p.t., indicating that they are in principle capable of uncoating. However, the HSPG-dependent, clathrin-independent cell entry pathway suffered from less efficient intracellular processing of mutants since despite adjusted intracellular particle numbers significantly fewer transcripts were detected for the HSPG-binders D5 and B1 (at the low particle-to-cell ratio) compared with rAAV2, A2 or C2 (Figure 5b ).
To determine if vectors entering by an HSPG-dependent, clathrinand caveolin-independent pathway are less efficiently routed to the nuclear area than rAAV2, we performed HeLa cell transduction at a particle-to-cell ratio of 2Â10 2 with the HSPG binders B1, D5 and rAAV2, and measured the number of vector genomes in the cytosolic fraction, the membrane fraction and the nuclear fraction at 2 h p.t., the time point when transcripts became detectable ( Figure 5) . Irrespective of the specific vector, the majority of vector genomes were found in the membrane and nuclear fractions, whereas only few vector genomes were detected in the cytosolic fraction (Supplementary Table 3) .
To compare the efficiency of intracellular routing, we calculated the ratio between the vector genomes found in the membrane fraction and those in the nuclear fraction. Figure 6a shows that the ratios obtained for B1 and D5 were significantly higher than the ratio for rAAV2, indicating that at 2 h p.t. a greater proportion of vector genomes of the HSPG binders B1 and D5 still localized to membrane-coated cellular compartments-presumably endosomescompared with rAAV2.
Collectively, these results argue for less efficient nuclear delivery of vector genomes when rAAV vectors are internalized by an One-way ANOVA using the Bonferroni method for all pairwise multiple comparison was performed to test for significant differences between rAAV2, B1 and D5. **Po0.01; ns, not significant. (b) Proteins extracted from the cytosolic (Cyt), membrane (Mem) and nuclear fractions (Nuc) or from total cell lysate (Tot) were detected by western blotting. Cytosolic and nuclear proteins were detected with antibodies against Akt and LaminB, and proteins in cellular membranes by anti-Rab5 antibody.
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DISCUSSION
Cell surface targeting approaches hold promise to improve safety and efficacy of in vivo gene therapy by reducing vector dosage and toxicity. To achieve this aim, viral tropism should be restricted to the desired ligand-receptor interaction, while natural receptor binding should be eliminated. HSPG, a negatively charged cell surface molecule, has been identified as primary receptor for AAV2. 5 Two of the five residues of the HSPG binding motif, R585 and R588, flank the commonly used peptide insertion site 587. 1, 6, 7 Upon peptide insertion, R585 and R588 become separated leading to the disruption of the natural HSPG binding motif. As we have previously shown, however, peptide insertions with a net positive charge at capsid position 587 of rAAV2 can restore HSPG binding. 12 To determine the effects of HSPG-binding and non-binding ligands on the internalization pathway and the intracellular fate of AAV2 targeting vectors, we here investigated early steps in vector transduction of four mutants each with a 7-mer peptide insertion (plus linker) at amino acid position 587 of the AAV2 capsid. As expected, 12 the two mutants (B1 and D5) displaying positively charged peptides possessed the capacity for HSPG binding (Figure 1 ). The affinity for heparin/HSPG was even stronger for D5 than that for rAAV2 as indicated by the significantly lower heparin concentration required to inhibit cell transduction (IC 50 0.08 IU ml À1 for D5 vs 0.8 IU ml À1 for rAAV2). Presumably, this is due to the repetition of the BXXB motif, which is found in the natural HSPG-binding motif (R 585 XXR 588 ) of AAV2 and is repeated in D5 to yield a BXXBXXBXXB motif (R 585 asaKGTKAPKaaR 588 ).
D5 is internalized into HeLa cells with an efficacy similar to rAAV2 (Figure 2 ), but surprisingly, neither clathrin-nor caveolin-mediated endocytosis appears to be involved in this process (Figure 3a and Supplementary Figure 1) . Interestingly, cationic DNA complexes are efficiently internalized by clathrin-independent and caveolinindependent routes following HSPG and in particular syndecan binding. 25 However, nuclear delivery of cationic DNA complexes via this pathway is inefficient. 26 Indeed, D5 had the lowest transduction efficiency (Figures 1a and 4 ) and transcript level ( Figure 5 ), and significantly fewer vector genomes were found in the nuclear fraction of HeLa cells transduced with D5 compared with rAAV2 ( Figure 6a) . B1, the second HSPG-binding mutant, possesses a lower affinity for HSPG (and heparin) than D5 and rAAV2 (Figure 1b) . Further analysis revealed that B1 is unique in its ability to employ at least two different cell entry pathways: (i) clathrin-mediated endocytosis and (ii) HSPGdependent (but clathrin-and caveolin-independent) internalization. The binding affinity of B1 for the as yet unidentified receptor mediating clathrin-dependent cell entry is probably as low as B1's affinity for the heparin receptor (Figure 3d) , as CPZ, a drug that inhibits the assembly of clathrin lattices, prevented clathrin-dependent transduction only at higher particle-to-cell ratios. In contrast to D5 and B1, rAAV2, A2 and C2 are internalized by the clathrin-dependent pathway (see Figure 3a and Pellinen and Ivaska 17 ). In case of rAAV2, however, HSPG binding is required as addition of heparin abolishes the transduction capability of rAAV2 ( Figure 1 ) and amino-acid substitutions in the HSPG-binding motif render rAAV2 non-infectious. 6, 7 Asokan and co-workers 9 recently proposed that HSPG binding induces a conformational change in the AAV2 capsid that subsequently allows co-receptor binding and virus/vector internalization by clathrin-mediated endocytosis. Alternatively, cell surface receptor clustering induced by HSPG binding 27 may bring rAAV2 in close contact with its internalization receptors, thereby enhancing the probability of cell entry. Here, we provide evidence that HSPG may directly function as an internalization receptor for rAAV2 when clathrin-mediated endocytosis is blocked. This assumption is based on the additive reduction in transduction efficiency observed for rAAV2 in the presence of heparin (IC 50 ) and CPZ compared with each drug alone (Figure 3d) .
The non-HSPG-binding mutants A2 and C2 were internalized into HeLa cells like rAAV2 by a clathrin-dependent pathway, although in contrast to rAAV2, entry efficiency was low. This may be accounted for by the fact that A2 and C2 lack the benefit of HSPG-mediated cell surface receptor clustering. However, by increasing target receptor expression or the particle-to-cell ratio, the likelihood of receptor engagement is increased and may result in an internalization efficiency that outperforms rAAV2.
Ligand-mediated changes in vector internalization have also been reported for other vectors, such as surface-engineered lentiviral vectors and a liposomal nano-carrier. 28, 29 Briefly, the Sindbis-virus-envelopepseudotyped lentiviral vector enters cells like native Sindbis virus by clathrin-mediated endocytosis and not by direct fusion with the plasma membrane, which is naturally the case for lentiviruses. 28 Similarly, a liposomal nano-carrier with an incorporated IRQ-peptide ligand was directed to caveolin-and clathrin-mediated uptake instead of macropinocytosis. 29 Furthermore, viral and non-viral vectors could successfully be targeted to distinct endocytic pathways, for example the clathrin-dependent entry route, by insertion of ligands such as transferrin or RGD-containing peptides. [30] [31] [32] In line with this, the mechanism of cell entry differed significantly among the here investigated capsid insertion mutants and in comparison to rAAV2 (Figure 7) . AAV2 binding to integrin is thought to induce clathrin-mediated endocytosis, but also cytoskeletal rearrangements, that facilitate trafficking of AAV2 (inside endosomes) from the periphery of the cell towards the nucleus. 10, 16, 33 Endosomal escape is mediated by lipolytic pore formation via phospholipase A2 activity upon endosomal acidification. [34] [35] [36] The latter also leads to the exposure of additional domains required for nuclear delivery of vector/viral genomes. 37 In view of the reliance of AAV2 on such specific intracellular conditions for successful infection, it is not surprising that ligands that direct rAAV targeting vectors to alternative pathways can lead to less efficient intracellular processing and lower transduction efficiency.
Inefficient processing of tropism-modified vectors is not unique to rAAV targeting vectors. Shayakhmetov and co-workers 38 reported that an adenoviral vector in which the adenovirus serotype 35 (Ad35) fiber knob had been introduced to obtain a chimeric Ad5/Ad35 vector was internalized via CD46 instead of CAR, the adenoviral serotype 5 receptor. Unlike Ad5, which escaped from early endosomes within 2 h p.i. and accumulated mostly in the cytosol or perinuclear space, the majority of Ad5/Ad35 chimeric vectors were still located in the endosomal compartment. The authors concluded that chimeric Ad5/Ad35 vectors internalized via CD46 were directed to a less efficient intracellular trafficking route that probably trapped the majority of viruses in late/lysosomal compartments.
In our study, we observed that internalization via an HSPGdependent, clathrin-independent pathway resulted in the accumulation of viral vector particles in membrane-surrounded organelles, most likely endosomes, and consequently in significantly lower transcript and cell transduction levels. This is in marked contrast to vectors that used clathrin-dependent endocytosis. The majority of genomes delivered by these vectors were detected in the nuclear fraction (Figure 6a and Supplementary Table 3 ) and significantly higher levels of transcription and cell transduction were observed (Figures 4 and 5) . Given the reliance of rAAV2 on acidificationtriggered conformational capsid change for successful transduction, it seems reasonable that the endosomal compartment entered by B1 and D5 following HSPG-mediated cell entry cannot provide equally efficient conditions for this step. However, further investigations will be needed to clarify this issue.
In summary, we here investigated for the first time how peptide ligands inserted in the rAAV capsid determine cell binding, the mode of vector internalization and the intracellular fate (Figure 7 ). Based on our findings, the ideal rAAV vector should be targeted to surface receptors with high levels of expression on the target cell that mediate HSPG-independent, clathrin-dependent transduction.
MATERIALS AND METHODS
Cell lines
The human embryonic kidney cell line HEK293 (ATCC number: CRL-1573), the cervix carcinoma cell line HeLa (ATCC number: CCL-2) and the human hepatoma cell line HepG2 (ATCC number: HB-8065) were maintained in Dulbecco's modified Eagle's medium with GlutaMAX-I (Invitrogen, Karlsruhe, Germany), supplemented with 10% fetal calf serum (Invitrogen), 100 IU ml À1 of penicillin (Invitrogen) and 100 mg ml À1 of streptomycin (Invitrogen). The human melanoma cell line BLM (kindly provided by Cornelia Mauch, Department of Dermatology, University Hospital Cologne, Cologne, Germany) and the human chronic myelogenous leukemia cell line K-562 (ATCC number: CCL-243) were maintained in RPMI-1640 medium with GlutaMAX-I (Invitrogen) supplemented with 10% fetal calf serum, 100 IU ml À1 of penicillin (Invitrogen) and 100 mg ml À1 of streptomycin (Invitrogen). All cell lines were cultivated in a humidified incubator with 5% CO 2 at 37 1C. Figure 7 Consequences of non-natural receptor binding-a model. We studied four rAAV2 capsid insertion mutants, two with peptides of neutral charge (A2 and C2) and two with a net positive charge (B1 +1 and D5 +3) inserted at position 587, thereby interfering with the integrity of the natural HSPGbinding motif of AAV2. Our study shows that peptide insertions at that region of the AAV2 capsid alter the internalization mode, the efficacy of cell entry and the intracellular processing of the targeting vector compared with the parental AAV2 serotype. rAAV2 binds to HSPG, its primary attachment receptor, followed by co-receptor engagement and clathrin-mediated endocytosis. When the clathrin internalization pathway is blocked, AAV2 seems to be able to use HSPG as an alternative internalization receptor. Unlike rAAV2, the peptide insertion mutants A2 and C2 neither use HSPG as an attachment receptor nor as an internalization receptor, but rely on a novel ligand-receptor interaction for clathrin-dependent uptake into the cell. Depending on the abundance of the receptor on the cell surface, this step may limit transduction efficiency as only few particles were capable of receptor binding and internalization. Nevertheless, if internalization occurs, intracellular processing of peptide insertion mutants via this pathway results in successful nuclear delivery of vector genomes, with efficacies comparable to rAAV2. In cases where the affinity for receptors mediating internalization via clathrin is low (B1), interaction with the HSPG network through a positively charged peptide insertion facilitates the binding to this receptor. Furthermore, HSPG itself is capable of promoting vector internalization. This pathway is used as an alternative entry route by B1 in particular at low particle-to-cell ratios or when the clathrin-mediated endocytic pathway is blocked, and seems to be the sole entry route for D5, a high-affinity HSPG-binding mutant. This pathway facilitates efficient internalization, although, as in non-viral vector gene transfer, nuclear delivery may be inefficient. Hence, high numbers of intracellular particles are needed for successful target cell transduction. Although further experimental evidence is required, our results support the view that endosomal escape of AAV virions limits the efficacy of the HSPG internalization pathway.
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Selection of AAV capsid insertion mutants
The ligand sequences of A2, B1, C2 and D5 were selected by AAV peptide display 39 on K-562 cells. Selection pressure was increased from round 1 to 3 by reducing the viral particle per cell number from 1000 to 1. Following the third selection cycle, selected sequences were identified by DNA sequencing (Qiagen, Hilden, Germany) as described. 39 The sequences A2, B1, C2 and D5 were chosen for further analysis (Supplementary Table 1 ). Oligonucleotides containing the ligand sequences flanked by an Ala-Ser-Ala and an Ala-Ala linker at the 5¢ and 3¢ end, respectively (Supplementary Table 4 ), were sticky-end ligated into pRC'99 as described 40 resulting in the plasmids pRC'99-A2, pRC'99-B1, pRC'99-C2 and pRC'99-D5.
Production of rAAV2 and rAAV capsid insertion mutants rAAV2 and the rAAV2 capsid insertion mutants A2, B1, C2 and D5 were produced in HEK293 cells by the adenovirus-free production method. 41 Briefly, cells were co-transfected by the calcium phosphate method with pXX6-80, 41 pGFP, 42 and pRC, 43 pRC'99-A2, pRC'99-B1, pRC'99-C2 or pRC'99-D5. At 48 h post-transfection, cells were lysed, treated with benzonase and further purified by iodixanol step gradient centrifugation. 42 All vector preparations used in this study contain a single-stranded vector genome conformation and encoded for enhanced GFP controlled by the cytomegalovirus promoter, and the hygromycin resistance gene controlled by the herpes simplex virus thymidine kinase promoter. Genomic particle titers were determined by real-time LightCycler PCR (Roche Diagnostics, Mannheim, Germany) 44 and transgene-specific primers (Supplementary Table 4 ). The capsid particle titer was determined by enzyme-linked immunosorbent assay using the anti-AAV capsid-specific antibody A20 (kindly provided by Jürgen Kleinschmidt, DKFZ Heidelberg, Germany) as described. 43 
Drug treatments
HeLa cells were incubated with CPZ at a final concentration of 10 mg ml À1 or with genistein at a final concentration of 200 mM or with MG-132 (carbobenzoxy-Leu-Leu-leucinal) at a final concentration of 10 mM for 30 min at 37 1C. Viral vectors were added at the indicated particle-to-cell ratio to drug-treated or -untreated cells. In case of CPZ or genistein treatment, transduction was stopped after 2 h by washing with 1ÂPBS, followed by extensive treatment with trypsin to remove membrane-bound vector particles 10, 16, 45 and re-seeding of the cells in fresh medium. Cells treated with MG-132 were washed with 1ÂPBS 4 h p.t. and fresh medium was added. Heparin was added to viral vectors at the indicated concentrations; solution was incubated for 30 min at room temperature and subsequently added to CPZ-untreated or -treated HeLa cells ( Figure 3 ). As control, HeLa cells were incubated with viral vectors in the absence of heparin or heparin/CPZ (Figure 3 ). Transgene-expressing cells were determined by flow cytometry 24 h p.t. using a BD FACS Calibur (Becton Dickinson, Heidelberg, Germany). A minimum of 5000 cells was counted for each sample. The background fluorescence level was set to 1%. The uptake of fluorescent dye-labeled transferrin (Alexa Fluor 488 conjugate; Invitrogen Molecular Probes, Karlsruhe, Germany) was assessed in CPZ-treated and -untreated HeLa cells seeded on 12-mm coverslips. Cells were incubated with 0.5 mg ml À1 of transferrin-Alexa488 for 2 h at 37 1C, washed with 1ÂPBS and nuclei were counterstained with 4¢,6-diamidino-2-phenylindole (SigmaAldrich, Taufkirchen, Germany). Embedded cells were analyzed by fluorescence microscopy (Axiophot, Carl Zeiss AG, Oberkochen, Germany).
Quantification of vector internalization efficacy
HeLa cells, seeded at 80% confluence in a 12-well plate, were incubated with rAAV2 or the capsid insertion mutants for 1 h on ice and then shifted to 37 1C. Cells were harvested at the indicated time points. The supernatant was removed and cells were washed with 1ÂPBS. Cells were extensively treated with trypsin to remove membrane-bound vector particles. 10, 16, 45 The cell pellet was washed twice with 1ÂPBS and total DNA was isolated (DNeasy Tissue Kit; Qiagen). Relative quantification of vector genomes and reference gene (plasminogen activator, Plat) was performed by qPCR (LC System; Roche Diagnostics). PCR amplification was performed (for primer sequences see Supplementary Table  4 
Quantification of vector genome transcripts
HeLa cells seeded at 80% confluence in a 12-well plate were incubated with rAAV2 or the capsid insertion mutants for 1 h on ice and then shifted to 37 1C. Following 1 h incubation at 37 1C, the medium was exchanged to medium containing 3% anti-capsid antibody A20 (kindly provided by Jürgen Kleinschmidt) to avoid further cell entry of vector particles. At the indicated time points, cells were harvested by removing the supernatant, washing twice with 1ÂPBS and lysing the cells in buffer RLT (RNeasy Mini Kit; Qiagen) containing 1% b-mercaptoethanol. Total RNA was extracted (RNeasy Mini kit; Qiagen) and cDNA was synthesized (SuperScript III First-Strand Synthesis SuperMix for qRT-PCR; Invitrogen). Relative quantification of vector genome transcripts and reference transcripts (d-aminolevulinate synthase I (AlasI) was performed (LC System; Roche Diagnostics; for primer sequences see Supplementary Table 4 ). The specificity of target and reference cDNA amplification was confirmed by melting-curve analysis. GFP values were normalized to AlasI levels using the LightCycler 480 software 1.5 (Roche Diagnostics).
Quantification of vector genomes in subcellular fractions
HeLa cells seeded at 80% confluence in 10 cm 2 cell culture plates were incubated with rAAV2 or the capsid insertion mutants for 1 h on ice and then shifted to 37 1C. Following 1 h incubation at 37 1C, the medium was exchanged to medium containing 3% anti-capsid antibody A20 (kindly provided by Jürgen Kleinschmidt). At 2 h p.t., the supernatant was removed, cells were washed with 1ÂPBS and harvested by extensive trypsin treatment. Cell pellet was washed twice with 1ÂPBS. Subcellular fractionation (Qproteome Cell Compartment Kit; Qiagen) was then performed as follows: cells were resuspended in cytosol extraction buffer and spun down. Supernatant was collected as cytosolic fraction. The pellet was resuspended in membrane extraction buffer and spun down. Supernatant was collected as membrane fraction. The pellet was resuspended in nuclear extraction buffer and spun down. Supernatant was collected as nuclear fraction. The fractions were divided for qPCR and western blot analysis, respectively. For quantification of vector genomes, 200 ml of the cytosolic, membrane and nuclear fraction was spiked with 2 ng of the plasmid pLuci (kindly provided by Sibille Quadt-Humme, University of Cologne, Cologne, Germany), which served as reference gene. Total DNA was extracted (DNeasy Tissue Kit; Qiagen) and relative quantification of vector genomes and reference gene was performed by qPCR (LC System; Roche Diagnostics; for primer sequences see Supplementary Table 4 ). The specificity of target and reference DNA amplification was confirmed by melting-curve analysis. GFP values were normalized to Luciferase levels using the LightCycler 480 software 1.5 (Roche Diagnostics). Purity of cytosolic, membrane and nuclear fraction was assayed by western blot analysis: total protein was extracted by resuspending the cell pellet in radioimmunoprecipitation assay buffer (50 mM Tris, pH 8.0; 150 mM NaCl, 0.5% deoxycholic acid, 0.1% sodium dodecyl phosphate, 1% NP-40) and incubated on ice for 30 min. Following centrifugation (16 000 g, 30 min, 4 1C), supernatant was collected. To increase protein concentration, acetone precipitation was conducted. Briefly, four volumes of ice-cold acetone were added to the sample, followed by 15 min incubation on ice. Following centrifugation (12 000 g, 10 min, 4 1C) supernatant was discarded, the pellet was air-dried and resuspended in 1ÂPBS. Samples were separated on 8 and 12% sodium dodecyl sulfate-polyacrylamide gel electrophoresis and blotted onto a nitrocellulose membrane. The membrane was blocked with 5% milk powder and 0.1% Tween 20 in 1ÂPBS. Detection of AKT (cytosolic fraction), LaminB (nuclear fraction) and Rab5 (membrane fraction) was performed using anti-AKT (1:1000; Cell Signaling Technologies Inc., Danvers, MA, USA), antiLaminB (1:500; Santa Cruz Biotechnology Inc., Santa Cruz, CA, USA) and anti-Rab5 (1:1000; Santa Cruz Biotechnology Inc.) as primary and the appropriate horseradish peroxidase-conjugated antibody as secondary antibodies.
Statistical analysis
Statistical analyses were carried out with Student's t-test, one-way analysis of variance (ANOVA) or two-way ANOVA. Multiple comparison procedures were Cell transduction of capsid-engineered rAAV vectors S Uhrig et al performed with Bonferroni or Holm-Sidak methods using the SigmaPlot Software (Systat Software Inc., Erkrath, Germany). P-values o0.05 were considered statistically significant. Three gradations were used to illustrate the magnitude of significance: ***Po0.001; **Po0.01; and *Po0.05.
